I think they realized back in July that the vaccine hill was too steep to climb and have handed testing and development off to a Chinese company, with royalties from direct Chinese marketing and retaining marketing rights for themselves through any other worldwide entity, and that we are simply waiting for Chinese clinical trials to progress far enough to make an application to the FDA for consideration and approval. This could simply be an extension of the existing iikey deal.
And that we will hear something soon about other GNBT subsidiary activities...especially activities associated with Excellagen.
No evidence for any of this but it is a blank slate so there is my screechy scribble for today. As always JMHO.
Happy Sunday everyone.
(5)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links